# Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients.

> **NCT05740150** · NA · UNKNOWN · sponsor: **Princess Maxima Center for Pediatric Oncology** · enrollment: 462 (estimated)

## Conditions studied

- Central Line-associated Bloodstream Infection (CLABSI)

## Interventions

- **DEVICE:** TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)
- **DEVICE:** Heparin lock (heparin 100 IU/mL)

## Key facts

- **NCT ID:** NCT05740150
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-27
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 462 (ESTIMATED)
- **Last updated:** 2023-02-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740150, "Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05740150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*